JP2527860B2 - チエノ〔２，３−ｂ〕〔１，５〕ベンゾジアゼピン誘導体及び該誘導体を含有する抗精神病薬組成物 - Google Patents

チエノ〔２，３−ｂ〕〔１，５〕ベンゾジアゼピン誘導体及び該誘導体を含有する抗精神病薬組成物

Info

Publication number: JP2527860B2
Authority: JP; Japan
Prior art keywords: compound; formula; methyl; acid; thieno
Prior art date: 1990-04-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP3228215A

Other languages

English (en)

Japanese (ja)

Other versions

JPH0789965A (ja

Inventor

クマーチャクラバルティイーバン

マイケルホッテンテランス

エドワードタッパーディヴィッド

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Lilly Industries Ltd

Original Assignee

Lilly Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-04-25

Filing date

1991-04-24

Publication date

1996-08-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10674942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2527860(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-04-24 Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd

1995-04-04 Publication of JPH0789965A publication Critical patent/JPH0789965A/ja

1996-08-28 Application granted granted Critical

1996-08-28 Publication of JP2527860B2 publication Critical patent/JP2527860B2/ja

2011-08-28 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims description 27
230000000561 anti-psychotic effect Effects 0.000 title claims description 7
HIQLUSHCRDHVDH-UHFFFAOYSA-N 2h-thieno[2,3-b][1,5]benzodiazepine Chemical class N1=CC2=CCSC2=NC2=CC=CC=C21 HIQLUSHCRDHVDH-UHFFFAOYSA-N 0.000 title 1
150000003839 salts Chemical class 0.000 claims abstract description 20
239000002253 acid Substances 0.000 claims abstract description 18
150000001875 compounds Chemical class 0.000 claims description 72
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 10
239000002775 capsule Substances 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 6
125000004193 piperazinyl group Chemical group 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 9
210000003169 central nervous system Anatomy 0.000 abstract description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
208000035475 disorder Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
239000004480 active ingredient Substances 0.000 description 13
239000003814 drug Substances 0.000 description 13
239000002904 solvent Substances 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 12
229940079593 drug Drugs 0.000 description 12
239000000243 solution Substances 0.000 description 11
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
102000005962 receptors Human genes 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
229920002472 Starch Polymers 0.000 description 8
239000000543 intermediate Substances 0.000 description 8
239000008107 starch Substances 0.000 description 8
235000019698 starch Nutrition 0.000 description 8
239000000126 substance Substances 0.000 description 8
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
201000000980 schizophrenia Diseases 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
JBHUBOISLBWHAR-UHFFFAOYSA-N Flumezapine Chemical compound C1CN(C)CCN1C1=NC2=CC(F)=CC=C2NC2=C1C=C(C)S2 JBHUBOISLBWHAR-UHFFFAOYSA-N 0.000 description 6
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
229950005785 flumezapine Drugs 0.000 description 6
238000009472 formulation Methods 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
238000012360 testing method Methods 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
150000001408 amides Chemical class 0.000 description 5
239000000164 antipsychotic agent Substances 0.000 description 5
229940005529 antipsychotics Drugs 0.000 description 5
-1 hydrochloric acid Chemical class 0.000 description 5
239000000047 product Substances 0.000 description 5
238000006798 ring closing metathesis reaction Methods 0.000 description 5
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
208000028017 Psychotic disease Diseases 0.000 description 4
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
150000001409 amidines Chemical class 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
238000000034 method Methods 0.000 description 4
239000012299 nitrogen atmosphere Substances 0.000 description 4
229920001296 polysiloxane Polymers 0.000 description 4
239000012312 sodium hydride Substances 0.000 description 4
229910000104 sodium hydride Inorganic materials 0.000 description 4
239000007787 solid Substances 0.000 description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 3
208000027776 Extrapyramidal disease Diseases 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
229910021626 Tin(II) chloride Inorganic materials 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000009194 climbing Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
229960003638 dopamine Drugs 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000012458 free base Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
235000019341 magnesium sulphate Nutrition 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000010992 reflux Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
235000011150 stannous chloride Nutrition 0.000 description 3
239000000725 suspension Substances 0.000 description 3
150000003573 thiols Chemical class 0.000 description 3
AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 3
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 3
PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 2
FDWMAKNNNPSUTL-UHFFFAOYSA-N 2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-amine hydrochloride Chemical compound Cl.N1C2=CC=CC=C2N=C(N)C2=C1SC(C)=C2 FDWMAKNNNPSUTL-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
206010003591 Ataxia Diseases 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
208000009132 Catalepsy Diseases 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
206010047853 Waxy flexibility Diseases 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical group C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
229960004046 apomorphine Drugs 0.000 description 2
239000002585 base Substances 0.000 description 2
238000009227 behaviour therapy Methods 0.000 description 2
238000004820 blood count Methods 0.000 description 2
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
230000001143 conditioned effect Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
229940109239 creatinine Drugs 0.000 description 2
230000006735 deficit Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
238000002955 isolation Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
238000002156 mixing Methods 0.000 description 2
150000002828 nitro derivatives Chemical class 0.000 description 2
LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229920001021 polysulfide Polymers 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000006722 reduction reaction Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000002002 slurry Substances 0.000 description 2
229950001675 spiperone Drugs 0.000 description 2
238000003756 stirring Methods 0.000 description 2
101150035983 str1 gene Proteins 0.000 description 2
GLBQVJGBPFPMMV-UHFFFAOYSA-N sulfilimine Chemical compound S=N GLBQVJGBPFPMMV-UHFFFAOYSA-N 0.000 description 2
229930192474 thiophene Natural products 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
QDNZOKVNXSYLLU-UHFFFAOYSA-N (2-ethoxy-2,4-dihydro-1h-quinolin-3-ylidene)methanone Chemical compound C1=CC=C2CC(=C=O)C(OCC)NC2=C1 QDNZOKVNXSYLLU-UHFFFAOYSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
ZVAPWJGRRUHKGP-UHFFFAOYSA-N 1h-1,5-benzodiazepine Chemical compound N1C=CC=NC2=CC=CC=C12 ZVAPWJGRRUHKGP-UHFFFAOYSA-N 0.000 description 1
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
YGXADLPRHBRTPG-UHFFFAOYSA-N 2-amino-5-methylthiophene-3-carbonitrile Chemical compound CC1=CC(C#N)=C(N)S1 YGXADLPRHBRTPG-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
NPXUFPFFHANGDL-UHFFFAOYSA-N 5-methyl-2-(2-nitroanilino)thiophene-3-carbonitrile Chemical compound S1C(C)=CC(C#N)=C1NC1=CC=CC=C1[N+]([O-])=O NPXUFPFFHANGDL-UHFFFAOYSA-N 0.000 description 1
201000010000 Agranulocytosis Diseases 0.000 description 1
206010001540 Akathisia Diseases 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010018687 Granulocytopenia Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
208000020186 Schizophreniform disease Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000003929 Transaminases Human genes 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
NVVVXCDSGMPBCB-UHFFFAOYSA-N [2-(2-aminoanilino)-5-methylthiophen-3-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=C(NC=2C(=CC=CC=2)N)SC(C)=C1 NVVVXCDSGMPBCB-UHFFFAOYSA-N 0.000 description 1
208000024453 abnormal involuntary movement Diseases 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
230000009471 action Effects 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000001022 anti-muscarinic effect Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000010531 catalytic reduction reaction Methods 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
229960004170 clozapine Drugs 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
JSYGRUBHOCKMGQ-UHFFFAOYSA-N dichloramine Chemical compound ClNCl JSYGRUBHOCKMGQ-UHFFFAOYSA-N 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
208000010118 dystonia Diseases 0.000 description 1
230000002828 effect on organs or tissue Effects 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
239000012634 fragment Substances 0.000 description 1
210000005153 frontal cortex Anatomy 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
201000000079 gynecomastia Diseases 0.000 description 1
229910052735 hafnium Inorganic materials 0.000 description 1
VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002631 hypothermal effect Effects 0.000 description 1
125000001841 imino group Chemical group [H]N=* 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000008141 laxative Substances 0.000 description 1
230000002475 laxative effect Effects 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910001510 metal chloride Inorganic materials 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
GHPDMFBHITXJAZ-UHFFFAOYSA-N methyl 2-amino-5-methylthiophene-3-carboxylate Chemical compound COC(=O)C=1C=C(C)SC=1N GHPDMFBHITXJAZ-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
ANGDWNBGPBMQHW-UHFFFAOYSA-N methyl cyanoacetate Chemical compound COC(=O)CC#N ANGDWNBGPBMQHW-UHFFFAOYSA-N 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
PBMIETCUUSQZCG-UHFFFAOYSA-N n'-cyclohexylmethanediimine Chemical compound N=C=NC1CCCCC1 PBMIETCUUSQZCG-UHFFFAOYSA-N 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000002474 noradrenergic effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000005077 polysulfide Substances 0.000 description 1
150000008117 polysulfides Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
229940001470 psychoactive drug Drugs 0.000 description 1
239000004089 psychotropic agent Substances 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
230000000698 schizophrenic effect Effects 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
210000002265 sensory receptor cell Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
CWXOAQXKPAENDI-UHFFFAOYSA-N sodium methylsulfinylmethylide Chemical compound [Na+].CS([CH2-])=O CWXOAQXKPAENDI-UHFFFAOYSA-N 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000001391 thioamide group Chemical group 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229910052720 vanadium Inorganic materials 0.000 description 1
GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
229910052726 zirconium Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Anesthesiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Cephalosporin Compounds (AREA)

JP3228215A 1990-04-25 1991-04-24 チエノ〔２，３−ｂ〕〔１，５〕ベンゾジアゼピン誘導体及び該誘導体を含有する抗精神病薬組成物 Expired - Lifetime JP2527860B2 (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB909009229A GB9009229D0 (en)	1990-04-25	1990-04-25	Pharmaceutical compounds
GB9009229.7		1990-04-25

Publications (2)

Publication Number	Publication Date
JPH0789965A JPH0789965A (ja)	1995-04-04
JP2527860B2 true JP2527860B2 (ja)	1996-08-28

Family

ID=10674942

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP3228215A Expired - Lifetime JP2527860B2 (ja)	1990-04-25	1991-04-24	チエノ〔２，３−ｂ〕〔１，５〕ベンゾジアゼピン誘導体及び該誘導体を含有する抗精神病薬組成物

Country Status (33)

Country	Link
EP (1)	EP0454436B1 (fi)
JP (1)	JP2527860B2 (fi)
KR (1)	KR100195566B1 (fi)
CN (1)	CN1028429C (fi)
AT (1)	ATE127804T1 (fi)
AU (1)	AU643267B2 (fi)
BG (1)	BG61710B2 (fi)
CA (1)	CA2041113C (fi)
CY (1)	CY1900A (fi)
CZ (1)	CZ279937B6 (fi)
DE (3)	DE69112895D1 (fi)
DK (1)	DK0454436T3 (fi)
ES (1)	ES2078440T3 (fi)
FI (1)	FI101379B1 (fi)
GB (1)	GB9009229D0 (fi)
GE (1)	GEP20032965B (fi)
GR (1)	GR3017877T3 (fi)
HK (1)	HK87596A (fi)
HU (2)	HU212416B (fi)
IE (1)	IE68401B1 (fi)
IL (2)	IL97912A (fi)
LU (2)	LU90009I2 (fi)
LV (1)	LV10262B (fi)
MX (1)	MX173791B (fi)
NL (2)	NL970015I2 (fi)
NO (3)	NO178766C (fi)
NZ (1)	NZ237932A (fi)
PT (1)	PT97446B (fi)
RU (1)	RU2043992C1 (fi)
SI (1)	SI9110739A (fi)
SK (1)	SK279196B6 (fi)
YU (1)	YU48049B (fi)
ZA (1)	ZA913085B (fi)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5817656A (en) *	1991-04-23	1998-10-06	Eli Lilly And Company	Mental disorders
US5817657A (en) *	1991-04-23	1998-10-06	Eli Lilly And Company	Psychoactive substance disorders
US5627178A (en) *	1991-04-23	1997-05-06	Lilly Industries Limited	2-methyl-thieno-benzodiazepine
US5817655A (en) *	1991-04-23	1998-10-06	Eli Lilly And Company	Methods of treatment using a thieno-benzodiazepine
ATE198891T1 (de) *	1992-05-29	2001-02-15	Lilly Co Eli	Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems
US6034078A (en) *	1992-05-29	2000-03-07	Eli Lilly And Company Limited	Thienobenzodiazepine compounds
JP3274579B2 (ja) *	1995-01-12	2002-04-15	住友製薬株式会社	脳血管障害に伴う精神症候治療剤
CR5278A (es) *	1995-03-24	1996-07-04	Lilly Co Eli	Formulacion oral de 2-metil-tieno-benzodiacepina
EP0733368A1 (en) *	1995-03-24	1996-09-25	Eli Lilly And Company	Granule fomulation for olanzapine
EG24221A (en) *	1995-03-24	2008-11-10	Lilly Co Eli	Process for preparing olanzapine
EG23659A (en) *	1995-03-24	2007-03-26	Lilly Co Eli	Process and crystal forms of methyl-thieno-benzodiazepine
US6506746B2 (en)	1995-05-30	2003-01-14	Eli Lilly And Company	Method for treating cognitive dysfunction
CN1131035C (zh) *	1995-05-30	2003-12-17	伊莱利利公司	治疗识别机能障碍的方法
PT828494E (pt) *	1995-05-30	2002-10-31	Lilly Co Eli	Compostos farmaceuticos
US5891461A (en) *	1995-09-14	1999-04-06	Cygnus, Inc.	Transdermal administration of olanzapine
JP2000502346A (ja) *	1995-12-21	2000-02-29	イーライ・リリー・アンド・カンパニー	皮膚炎の処置方法
UA57727C2 (uk) *	1996-03-11	2003-07-15	Елі Ліллі Енд Компані	Спосіб лікування надмірної агресивності
ZA978515B (en) *	1996-09-23	1999-03-23	Lilly Co Eli	Intermediates and process for preparing olanzapine
NZ334346A (en) *	1996-09-23	2000-05-26	Lilly Co Eli	Olanzapine dihydrate D comprising 2-methyl-4-(4-methyl-1-piperazinyl)-1OH-thieno[2,3-b][1,5]benzodiazepine and a formulation for use in treating central nervous system disorders
EP1016664B1 (en)	1997-09-02	2003-07-02	Mitsubishi Pharma Corporation	Fused thiophene compounds and medicinal use thereof
GB9718986D0 (en) *	1997-09-09	1997-11-12	Danbiosyst Uk	Controlled release microsphere delivery system
KR100537713B1 (ko) *	1997-09-30	2005-12-20	일라이 릴리 앤드 캄파니	2-메틸-티에노-벤조디아제핀 제제
FR2802101B1 (fr)	1999-12-10	2003-02-28	Aventis Pharma Sa	Association de cymemazine et d'un neuroleptique atypique
AU2001243475A1 (en)	2000-08-31	2002-03-13	Dr. Reddy's Laboratories Ltd.	Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
RU2185383C1 (ru) *	2001-05-22	2002-07-20	Институт молекулярной генетики РАН	ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ 2-МЕТИЛ-4-(4-МЕТИЛ-1-ПИПЕРАЗИНИЛ)-10Н-ТИЕНО[2,3-b][1,5]БЕНЗОДИАЗЕПИН
JP4530664B2 (ja) *	2001-12-24	2010-08-25	サン・ファーマシューティカル・インダストリーズ・リミテッド	２−メチル−４−（４−メチル−１−ピペラジニル）−１０Ｈ−チエノ［２，３−ｂ］［１，５］ベンゾジアゼピンの結晶形Ｉ、この結晶形Ｉの製造方法、及び医薬組成物
PL196814B1 (pl) *	2002-05-17	2008-02-29	Inst Farmaceutyczny	Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
SI1513846T1 (sl)	2002-05-31	2011-11-30	Sandoz Ag	Postopek za pripravo olanzapina form I
US20040063694A1 (en) *	2002-06-05	2004-04-01	Browder Monte R.	Compound useful for the treatment of CNS disorders
PL199016B1 (pl) *	2002-06-20	2008-08-29	Adamed Sp Z Oo	Sposób wytwarzania olanzapiny
SI21303A (sl)	2002-10-18	2004-04-30	Krka, Tovarna Zdravil, D.D.,, Novo Mesto	Farmacevtska formulacija olanzapina
PL202856B1 (pl) *	2002-12-20	2009-07-31	Adamed Spo & Lstrok Ka Z Ogran	Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
DE10301923B3 (de) *	2003-01-17	2004-09-16	Krka Tovarna Zdravil, D.D.	Verfahren und Zwischenprodukte zur Herstellung von Olanzapin
HU226410B1 (en)	2003-04-22	2008-11-28	Egis Gyogyszergyar Nyilvanosan	Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
EP1611139B1 (en)	2003-12-22	2008-06-04	Teva Pharmaceutical Industries Ltd.	Methods of preparing olanzapine
WO2005070937A1 (en) *	2004-01-27	2005-08-04	Synthon B.V.	A process for making olanzapine in a polymorph form i
EP1709053B1 (en)	2004-01-27	2011-04-06	Synthon B.V.	Stable salts of olanzapine
AR048272A1 (es) *	2004-03-18	2006-04-12	Lek Pharmaceuticals	Sintesis de 2 metil - 4- (4- metil -1- piperazinil) - 10 h- tieno ( 2,3-b) (1,5) benzodiazepina y sus sales, metodos para su preparacion, composiciones farmaceuticas que la contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mentales.
ES2253091B1 (es) *	2004-07-27	2007-02-01	Inke, S.A.	Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
SI21850A (sl) *	2004-07-28	2006-02-28	Krka, Tovarna Zdravil, D.D., Novo Mesto	Soli olanzapina in njihova pretvorba v prosto bazo olanzapina
CA2587710C (en) *	2004-11-16	2014-10-21	Elan Pharma International Ltd.	Injectable nanoparticulate olanzapine formulations
PL198589B1 (pl)	2004-11-22	2008-06-30	Adamed Sp Z Oo	Sposób wytwarzania N-demetyloolanzapiny
JP4940152B2 (ja)	2005-01-05	2012-05-30	イーライリリーアンドカンパニー	パモ酸オランザピン二水和物
HUP0501046A2 (en) *	2005-11-11	2007-08-28	Egis Gyogyszergyar Nyilvanosan	Process for the preparation of olanzapine
US7834176B2 (en)	2006-01-26	2010-11-16	Sandoz Ag	Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
CN100383144C (zh) *	2006-09-11	2008-04-23	杭州盛美医药科技开发有限公司	一种奥氮平的中间体及其制备与应用
US20080138409A1 (en) *	2006-09-29	2008-06-12	Osinga Niels J	Olanzapine pharmaceutical composition
PL381564A1 (pl)	2007-01-22	2008-08-04	Koźluk Tomasz Nobilus Ent	Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2593407A1 (en)	2007-06-22	2008-12-22	Apotex Pharmachem Inc.	Improved processes for the synthesis of olanzapine
CN101168544B (zh) *	2007-11-16	2010-11-17	西南合成制药股份有限公司	奥氮平的制备工艺
CN101735239B (zh) *	2008-11-06	2011-08-31	齐鲁制药有限公司	一种无水奥氮平晶型ii的制备方法
EP2292624A1 (en)	2009-07-20	2011-03-09	LEK Pharmaceuticals d.d.	Process for the purification of olanzapine
CN102532158A (zh) *	2010-12-17	2012-07-04	北大方正集团有限公司	一种合成奥氮平的方法
EP2486913A1 (en)	2011-02-14	2012-08-15	Labtec GmbH	Rapidly disintegrating oral film formulation for Olanzapin
WO2012153347A2 (en)	2011-05-04	2012-11-15	Zentiva K.S.	Oral pharmaceutical composition of olanzapine form 1
CN102225941B (zh) *	2011-06-01	2013-11-27	宁波人健医药化工有限公司	抗精神病药奥氮平的制备方法
WO2013066280A1 (en) *	2011-10-31	2013-05-10	Mahmut Bilgic	Water soluble antipsychotic formulations
JP5934004B2 (ja) *	2012-03-22	2016-06-15	株式会社トクヤマ	結晶構造を有する４−アミノ−２−メチル−１０Ｈ−チエノ〔２，３−ｂ〕〔１，５〕ベンゾジアゼピン塩酸塩水和物及びその製造方法
US20150216206A1 (en)	2012-07-31	2015-08-06	Sanovel Hayvan Sagligi Urunleri Sanayi Ve Ticaret Anonim Sirketi	Method for increasing meat and milk production
WO2014021803A1 (en)	2012-07-31	2014-02-06	Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret A.S.	Use of olanzapine in animals
JP6042153B2 (ja) *	2012-09-26	2016-12-14	株式会社トクヤマ	オランザピンの製造方法
KR101641902B1 (ko)	2015-06-24	2016-07-22	주식회사 네이처센스 농업회사법인	스트레스의 완화용 조성물
CN106265541A (zh) *	2016-08-31	2017-01-04	安徽省润生医药股份有限公司	一种注射用奥氮平及其制备方法
CN111004210A (zh) *	2019-10-23	2020-04-14	中山大学	化合物单晶及其制备方法
WO2025056094A1 (zh) *	2023-09-15	2025-03-20	广州帝奇医药技术有限公司	一种冻干制剂和注射液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU629879A3 (ru) *	1974-11-26	1978-10-25	Лилли Индастриз Лимитед, (Фирма)	Способ получени тиено(1,5) бензодиазепинов или их солей
US3953430A (en) *	1975-02-24	1976-04-27	American Cyanamid Company	Substituted benzodiazepin-10-ones and method of use
GB1533236A (en) *	1975-11-24	1978-11-22	Lilly Industries Ltd	Thieno(1,5)benzodiazepine intermediates
GB1577743A (en) *	1977-05-17	1980-10-29	Lilly Industries Ltd	Benzodiazepine derivatives

1990
- 1990-04-25 GB GB909009229A patent/GB9009229D0/en active Pending
1991
- 1991-04-22 IL IL9791291A patent/IL97912A/en not_active IP Right Cessation
- 1991-04-22 AU AU75186/91A patent/AU643267B2/en not_active Expired
- 1991-04-23 PT PT97446A patent/PT97446B/pt not_active IP Right Cessation
- 1991-04-23 IE IE134891A patent/IE68401B1/en not_active IP Right Cessation
- 1991-04-24 MX MX2550291A patent/MX173791B/es unknown
- 1991-04-24 CA CA002041113A patent/CA2041113C/en not_active Expired - Lifetime
- 1991-04-24 NZ NZ237932A patent/NZ237932A/en unknown
- 1991-04-24 JP JP3228215A patent/JP2527860B2/ja not_active Expired - Lifetime
- 1991-04-24 SI SI9110739A patent/SI9110739A/sl unknown
- 1991-04-24 DE DE69112895A patent/DE69112895D1/de not_active Expired - Lifetime
- 1991-04-24 KR KR1019910006544A patent/KR100195566B1/ko not_active Expired - Lifetime
- 1991-04-24 EP EP91303679A patent/EP0454436B1/en not_active Expired - Lifetime
- 1991-04-24 ZA ZA913085A patent/ZA913085B/xx unknown
- 1991-04-24 YU YU73991A patent/YU48049B/sh unknown
- 1991-04-24 HU HU911372A patent/HU212416B/hu active IP Right Revival
- 1991-04-24 DE DE1996175046 patent/DE19675046I2/de active Active
- 1991-04-24 LU LU90009C patent/LU90009I2/fr unknown
- 1991-04-24 ES ES91303679T patent/ES2078440T3/es not_active Expired - Lifetime
- 1991-04-24 DK DK91303679.4T patent/DK0454436T3/da active
- 1991-04-24 CY CY190091A patent/CY1900A/xx unknown
- 1991-04-24 SK SK1168-91A patent/SK279196B6/sk not_active IP Right Cessation
- 1991-04-24 FI FI911986A patent/FI101379B1/fi active Protection Beyond IP Right Term
- 1991-04-24 CN CN91103346A patent/CN1028429C/zh not_active Expired - Lifetime
- 1991-04-24 AT AT91303679T patent/ATE127804T1/de active
- 1991-04-24 DE DE69112895T patent/DE69112895T4/de not_active Expired - Lifetime
- 1991-04-24 NO NO911624A patent/NO178766C/no not_active IP Right Cessation
- 1991-04-24 CZ CS911168A patent/CZ279937B6/cs not_active IP Right Cessation
1992
- 1992-09-25 RU SU925052762A patent/RU2043992C1/ru active
1993
- 1993-06-08 LV LVP-93-517A patent/LV10262B/xx unknown
1994
- 1994-02-02 BG BG098434A patent/BG61710B2/bg unknown
1995
- 1995-02-08 IL IL11257595A patent/IL112575A0/xx unknown
- 1995-06-22 HU HU95P/P00335P patent/HU211575A9/hu unknown
- 1995-10-25 GR GR950402982T patent/GR3017877T3/el unknown
1996
- 1996-05-16 HK HK87596A patent/HK87596A/en not_active IP Right Cessation
1997
- 1997-03-21 NL NL970015C patent/NL970015I2/nl unknown
- 1997-05-12 NO NO1997005C patent/NO1997005I1/no unknown
2001
- 2001-10-18 GE GEAP20016159A patent/GEP20032965B/en unknown
- 2001-12-21 LU LU90869C patent/LU90869I2/fr unknown
- 2001-12-28 NO NO2001028C patent/NO2001028I1/no unknown
- 2001-12-28 NL NL300078C patent/NL300078I1/nl unknown

Also Published As

Publication number	Publication date
DE69112895D1 (de)	1995-10-19
DE19675046I2 (de)	2001-05-23
KR910018387A (ko)	1991-11-30
LU90869I2 (fr)	2002-02-21
NL970015I2 (nl)	1997-09-01
ATE127804T1 (de)	1995-09-15
HU211575A9 (en)	1995-12-28
JPH0789965A (ja)	1995-04-04
FI911986A0 (fi)	1991-04-24
PT97446A (pt)	1992-01-31
ES2078440T3 (es)	1995-12-16
ZA913085B (en)	1992-12-30
YU48049B (sh)	1996-10-18
DK0454436T3 (da)	1995-11-13
FI101379B (fi)	1998-06-15
DE69112895T4 (de)	2009-11-12
NO178766C (no)	1996-05-29
AU643267B2 (en)	1993-11-11
BG61710B2 (bg)	1998-03-31
NZ237932A (en)	1993-08-26
EP0454436B1 (en)	1995-09-13
IL97912A0 (en)	1992-06-21
IE911348A1 (en)	1991-11-06
NO178766B (no)	1996-02-19
HU212416B (en)	1996-06-28
CN1028429C (zh)	1995-05-17
KR100195566B1 (ko)	1999-06-15
MX173791B (es)	1994-03-25
NL300078I1 (nl)	2002-03-01
FI911986L (fi)	1991-10-26
HU911372D0 (en)	1991-10-28
NO1997005I1 (no)	1997-05-12
YU73991A (sh)	1994-01-20
NO911624L (no)	1991-10-28
LU90009I2 (fr)	1997-01-31
RU2043992C1 (ru)	1995-09-20
NL970015I1 (nl)	1997-06-02
NO2001028I1 (no)	2002-01-28
IE68401B1 (en)	1996-06-12
FI101379B1 (fi)	1998-06-15
LV10262A (lv)	1994-10-20
IL97912A (en)	1995-10-31
HK87596A (en)	1996-05-24
EP0454436A1 (en)	1991-10-30
CA2041113A1 (en)	1991-10-26
AU7518691A (en)	1991-11-07
SI9110739A (en)	1997-10-31
CN1056693A (zh)	1991-12-04
NO911624D0 (no)	1991-04-24
LV10262B (en)	1995-04-20
CZ279937B6 (cs)	1995-09-13
PT97446B (pt)	1997-07-31
GB9009229D0 (en)	1990-06-20
MX25502A (es)	1993-10-01
GEP20032965B (en)	2003-05-12
CS9101168A2 (en)	1991-12-17
CY1900A (en)	1991-04-24
CA2041113C (en)	1998-07-14
GR3017877T3 (en)	1996-01-31
IL112575A0 (en)	1995-05-26
SK279196B6 (sk)	1998-07-08
HUT60503A (en)	1992-09-28
DE69112895T2 (de)	1996-03-07

Publication	Publication Date	Title
JP2527860B2 (ja)	1996-08-28	チエノ〔２，３−ｂ〕〔１，５〕ベンゾジアゼピン誘導体及び該誘導体を含有する抗精神病薬組成物
US5229382A (en)	1993-07-20	2-methyl-thieno-benzodiazepine
US6008216A (en)	1999-12-28	Process for preparing 2-methyl-thieno-benzodiazepine
US5605897A (en)	1997-02-25	2-methyl-thieno-benzodiazepine
US5817656A (en)	1998-10-06	Mental disorders
ES2348453T3 (es)	2010-12-07	Compuestos de triciclicos y su uso como antagonistas de mglur1.
AU668159B2 (en)	1996-04-26	Pharmaceutical compounds
DE69630209T2 (de)	2004-08-19	Bicyclische benzazepin-derivate als vasopressin-antagonisten
US5817655A (en)	1998-10-06	Methods of treatment using a thieno-benzodiazepine
JPS60215683A (ja)	1985-10-29	新規縮合ジアゼピノン
SK282970B6 (sk)	2003-01-09	Deriváty 1H-pyrido[3,4-b]indol-4-karboxamidu, farmaceutická kompozícia, ktorá ich obsahuje, a spôsob ich prípravy
US5817657A (en)	1998-10-06	Psychoactive substance disorders
IE42564B1 (en)	1980-09-10	Benzodiazepine derivatives
US5175158A (en)	1992-12-29	Condensed diazepinones, processes for preparing them and pharmaceutical compositions containing these compounds
US5051516A (en)	1991-09-24	Benzodiazepine compounds and their use as pharmaceuticals
CZ290678B6 (cs)	2002-09-11	3-Substituované 3,4,5,7-tetrahydropyrrolo[3´,4´: 4,5]thieno[2,3-d]pyrimidinové deriváty, způsob jejich přípravy a použití
NZ240501A (en)	1992-05-26	4- or 5-(2-nitroanilino)thiazole derivatives
SA95160196B1 (ar)	2005-12-21	مركبات صيدلانية

Legal Events

Date	Code	Title	Description
1996-04-23	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 19960422
2004-06-01	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2005-05-31	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2005-07-19	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2011-02-09	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20160614 Year of fee payment: 20
2012-02-16	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2012-02-16	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20160614 Year of fee payment: 20
2012-02-22	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20160614 Year of fee payment: 20
2012-02-22	R153	Grant of patent term extension	Free format text: JAPANESE INTERMEDIATE CODE: R153
2014-11-10	S531	Written request for registration of change of domicile	Free format text: JAPANESE INTERMEDIATE CODE: R313531
2014-11-18	R350	Written notification of registration of transfer	Free format text: JAPANESE INTERMEDIATE CODE: R350
2014-11-18	S533	Written request for registration of change of name	Free format text: JAPANESE INTERMEDIATE CODE: R313533
2014-11-27	R350	Written notification of registration of transfer	Free format text: JAPANESE INTERMEDIATE CODE: R350
2016-04-24	EXPY	Cancellation because of completion of term